Phase I & II Trial Results

Trial Results

Phase I/II Melanoma Personalized Cancer Vaccine Trial

Toxicity

toxicity

Demographicsdemographics

*One patient excluded for recurrence prior to 12 week F/U (19 days); one patient lost to F/U

Overall survivaloverall-survival Gendergender
Ageage Initial Stage IVinitial-stage-iv
Initial Stage Iinitial-stage-i Time to treatmenttime-to-treatment
Overall survivaloverall-survival-2 No evidence of disease (NED)ned
# Inoculationinoculations